Paracoccidioidomycosis of the Central Nervous System: CT and MR Imaging Findings

M. Rosa Júnior, A.C. Amorim, I.V. Baldon, L.A. Martins, R.M. Pereira, R.P. Campos, S.S. Gonçalves, T.R.G. Velloso, P. Peçanha, and A. Falqueto

ABSTRACT

BACKGROUND AND PURPOSE: Paracoccidioidomycosis is a fungal infection mainly caused by the thermomorphous fungus *Paracoccidioides*. The purpose of our study was to demonstrate the neuroimaging findings from 24 patients with CNS paracoccidioidomycosis.

MATERIALS AND METHODS: We performed a retrospective analysis focusing on the radiologic characteristics of CNS paracoccidioidomycosis. The 24 selected patients underwent MR imaging and/or CT, and the diagnosis was made by the presence of typical neuroimaging features, combined with fungus isolation, a serologic test, or the presence of disseminated disease.

RESULTS: Headache was the most common neurologic symptom, while the pseudotumoral form was the most common pattern. The number of lesions ranged from 1 to 11, with most localized on the frontal lobe with >2-cm lesions. CT showed mainly hypodense lesions, whereas MR imaging demonstrated mainly hypointense lesions on T1WI and T2WI. Furthermore, ring enhancement was present in most patients. The “dual rim sign” on SWI occurred in 100% of our patients with lesions of >2 cm.

CONCLUSIONS: The diagnosis of CNS paracoccidioidomycosis is difficult. Nevertheless, imaging examinations can play an important role in the diagnosis and evaluation of the disease.

ABBREVIATIONS: PCM = paracoccidioidomycosis; CT = computed tomography; MRI = magnetic resonance imaging; CNS = central nervous system; DSC = dynamic susceptibility contrast; DCE = dynamic contrast enhanced; rCBV = relative cerebral blood volume; Gd = gadolinium

Paracoccidioidomycosis (PCM) is a fungal infection, which is endemic in Latin America and is mainly caused by the thermomorphous fungus *Paracoccidioides* spp, which primarily attacks the lungs and has a potential to disseminate to other organs.¹ Recently described are 4 other species of the genus *Paracoccidioides* apart from *P brasiliensis*: *P lutzii*, *P restrepiensis*, *P venezuelensis*, and *P Americana*.^{2,3}

Paracoccidioides spp inhabits primarily the soil and causes autochthonous infection from southern Mexico to northern Argentina.^{4–6} Most reported cases (approximately 80%) are from

Brazil, and the rest are mainly from Venezuela, Colombia, and Argentina.^{6–14}

The criterion standard for the diagnosis of PCM consists of demonstrating the presence of the fungus as multiple budding cells in clinical or tissue specimens. Nevertheless, serologic tests and imaging examinations such as CT, MR imaging, and x-rays also play an important role in the diagnosis and evaluation of the disease.^{1,5–17}

CNS involvement is more common than it was once believed, and the disease can affect the CNS, ranging from 1% to 27.27% of cases.^{18–25} Although the brain form of PCM is usually an outcome of hematogenous or lymphatic dissemination of a primary focus, it is not necessarily followed by disseminated PCM; in a few cases, it is the only location of the fungus in the body.²⁶

Our purpose was to describe the clinical and radiologic data (CT and MR imaging) of 24 patients diagnosed with CNS PCM between 1978 and 2019. To the best of our knowledge, this is the largest imaging study of CNS PCM.

MATERIALS AND METHODS

This was a retrospective study, focusing on the radiologic characteristics of patients with CNS PCM attending the University Hospital Cassiano Antônio de Moraes, Federal University of

Received June 19, 2019; accepted after revision July 25.

From the Departments of Neuroradiology (M.R.J.) and Radiology (A.C.A., I.V.B., L.A.M., R.M.P.), Hospital Universitário Cassiano Antônio de Moraes da Universidade Federal do Espírito Santo, HUCAM/UFES/EBSERH, Vitória, Espírito Santo, Brazil; Department of Neuroradiology (R.P.C.), Hospital Meridional, Cariacica, Espírito Santo, Brazil; and Departments of Pathology (S.S.G.), Clinical Dentistry (T.R.G.V.), and Infectious Disease (P.P., A.F.), Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil.

Please address correspondence to Marcos Rosa Júnior, MD, PhD, Universidade Federal do Espírito Santo, UFES, Centro de Ciências da Saúde, Maruípe, 29043900, Vitória, Espírito Santo, Brazil; e-mail: marcosrosajr@hotmail.com

Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A6203>

Table 1: Epidemiologic and clinical characteristics

Characteristic	Value
Age	
Median (range) (yr)	54 (19–66)
Subgroup (No. of patients) (%)	
0–19	1 (4.1)
20–39	6 (25.0)
40–59	11 (45.8)
≥60	6 (25.0)
Male sex (No.) (%)	24 (100)
Neurologic symptoms (No. of patients) (%)	
Headache	8 (33.3)
Epilepsy	7 (29.1)
Focal neurologic signs	6 (25.0)
Paresis	5 (20.8)
Paresthesia	4 (16.6)
Plegia	2 (8.3)
Dysarthria	2 (8.3)
Mental confusion	2 (8.3)
Head lump	2 (8.3)
Diplopia	1 (4.1)
Chorea	1 (4.1)
Vertigo	1 (4.1)
Absence of neurologic symptom	2 (8.3)

Table 2: CT findings

Characteristic	Value
Patterns (No. of patients) (%)	
Pseudotumoral	21 (87.5)
Meningeal	1 (4.1)
Pseudotumoral + meningeal (combined)	2 (8.3)
Calcifications (No. of patients) (%)	0 (0)
Perilesional edema (No. of patients) (%) ^a	19 (90.4)
Hydrocephalus (No. of patients) (%)	6 (25.0)
Hemorrhage (No. of patients) (%) ^b	3 (13.0)
No. of lesions ^b	
Mean (range)	3.0 (1–11)
Subgroup (No. of patients) (%)	
Single lesions	9 (39.1)
2–5	11 (47.8)
6–10	2 (8.6)
>10	1 (4.3)
Lesion size (No. of patients) (%) ^b	
>2 cm	15 (65.2)
Larger axial diameter of the major lesion ^b	
Mean (range) (cm)	2.6 (0.3–5.6)
CT attenuation (No. of patients) (%) ^c	
Hyperattenuating lesions	11 (20.7)
Hypoattenuating lesions	30 (56.6)
Hypoattenuating center and hyperattenuating margin	12 (22.6)
CT or MR imaging contrast enhancement (No. of patients) (%)	
Ring enhancement	17 (70.8)
Nodular enhancement	3 (12.5)
Ring and nodular enhancement	3 (12.5)
Leptomeningeal enhancement	1 (4.1)

^a This category considered only in the 21 patients with pseudotumoral form.

^b These categories excluded the patient with the meningeal form isolated.

^c Seven patients did not have CT scans and were eliminated from the calculations.

Table 3: Lesion sites

Characteristic	Value
Localization (No. of patients) (%)	
Basal meningitis	1 (4.1)
Pachymeningitis	1 (4.1)
Skull	2 (8.3)
Parietal lobe	7 (29.1)
Occipital lobe	6 (25.0)
Frontal lobe	9 (37.5)
Temporal lobe	5 (20.8)
Cerebellum	8 (33.3)
Cingulate gyrus	3 (12.5)
Thalamus	5 (20.8)
Basal ganglia	3 (12.5)
Striatum	1 (4.1)
Globus pallidus	1 (4.1)
Caudate nucleus	1 (4.1)
Putamen	1 (4.1)
Corpus callosum	2 (8.3)
Hippocampus	1 (4.1)
Hypothalamus	1 (4.1)
Pons	2 (8.3)

fungus isolation, a serologic test, or the presence of disseminated disease.

The CT scans were performed with Aquilion ONE 64-slice (Toshiba Medical Systems, Tokyo, Japan) or Asteion single-section (Toshiba Medical Systems) scanners. Patients were studied with 1-, 5-, or 10-mm axial slices before and/or after administration of an intravenous iodinated contrast agent in a peripheral vein at a total dose of 1.5 mL/kg. Fourteen patients underwent CT before and after contrast, and 3 patients, without contrast administration.

The MR images were obtained in a 1.5T Achieva (Philips Healthcare, Best, the Netherlands) or a 1.5T Brivo (GE Healthcare, Milwaukee, Wisconsin), with a specific head coil model with 8 channels, with T1-weighted, T2-weighted, FLAIR, DWI, T2*, and T1 postcontrast images. Intravenous administration of 0.1 mmol/kg of gadolinium-based contrast agent through the antecubital vein was performed for all patients. The MR imaging parameters were the following—Achieva: T1-weighted: TR = 547.8–623 ms, TE = 12.8–15 ms, section thickness = 5.0 mm, matrix = 528 × 528–328 × 271; T2-weighted: TR = 4572.5–4631 ms, TE = 100 ms, section thickness = 5.0 mm, matrix = 704 × 704–328 × 253; FLAIR: TR = 11,000 ms, TE = 140 ms, TI = 2800, section thickness = 5.0 mm, matrix = 640 × 640–256 × 156; DWI: TR = 4583–6596.3 ms, TE = 79–88.2 ms, section thickness = 3.5 mm, matrix = 512 × 512–192 × 114; T2*: TR = 588–609 ms, TE = 13.8 ms, section thickness = 5.0 mm, matrix = 512 × 512–232 × 183; SWI: TR = 22.6 ms, TE = 32.5 ms, section thickness = 2.0 mm, matrix = 448 × 448; T1 3D sagittal postcontrast fast-field echo: TR = 12.4 ms, TE = 5946 ms, section thickness = 1 mm, matrix = 288 × 288; Brivo: T1-weighted: TR = 728 ms, TE = 3 ms, section thickness = 5.5 mm, matrix = 416 × 192; T2-weighted: TR = 3625 ms, TE = 122 ms, section thickness = 4.5 mm, matrix = 416 × 192; DWI: TR = 7309 ms, TE = 117 ms, section thickness = 4.5 mm, matrix = 128 × 128; T2*: TR = 434 ms, TE = 15.8 ms, section thickness = 4.5 mm, matrix = 320 × 224; FLAIR: TR = 10,000 ms, TE = 110 ms, section thickness = 4.5 mm, matrix = 288 × 192; T1 3D sagittal postcontrast: TR = 7.9 ms, TE = 2.6 ms, section thickness = 2.0 mm, matrix = 288 × 224.

Espirito Santo, between 1978 to 2019. The 24 selected patients had MR imaging and/or CT scans, and the diagnosis was made by the presence of typical neuroimaging features, combined with

FIG 1. Brain CT showing different presentations of the lesions. A, Hypoattenuating lesions. B, Hypoattenuating lesions with a hyperattenuating halo. C, Hyperattenuating lesions.

FIG 2. Signal on the T1-weighted images: hypointense lesion (A), lesion with hypointense center and hyperintense halo (B), and hyperintense lesion (C).

FIG 3. T2-weighted images show a hypointense lesion (A), a heterogeneous signal (B), and a hyperintense lesion (C).

Five patients also underwent SWI, 2 patients underwent perfusion DSC and dynamic contrast-enhanced imaging, and 2 patients underwent spectroscopy studies, only with qualitative analyses.

Dynamic Contrast-Enhanced MR Imaging

A power injector was used to administer a bolus of gadolinium-based contrast agent at a dose of 0.05 mmol/kg and rate of 5 mL/s. The kinetic enhancement of tissue before and after contrast

injection was obtained using a 3D-T1-weighted fast-spoiled gradient-echo sequence (TR = 5.5 ms, TE = 1.3 ms, section thickness = 5 mm, flip angle = 12°, FOV = 240 × 177 × 125 cm, matrix = 108 × 100) and consisted of 25 images in the axial plane. Ten phases for preinjection time delay and 30 phases for postinjection were obtained.

DSC-PWI was performed with a gradient-recalled T2*-weighted echo-planar imaging sequence. The imaging parameters were as follows: TR/TE = 2085/40 ms, flip angle = 75°, section thickness = 5 mm, intersection gap = 0.5 mm, NEX = 1.0, FOV = 240 × 240 mm. During the first 3 phases, images were acquired before injecting the contrast material to establish a baseline. When the scan was in the fourth phase of DSC-PWI, a bolus of gadolinium-based contrast agent at a dose of 0.25 mmol/kg of body weight and 5 mL/s was injected intravenously with an MR imaging-compatible power injector. After we injected a bolus of the contrast material, a 20.0-mL bolus of saline was administered at the same injection rate. The series had 25 sections with 60 phases.

Single-voxel spectroscopy was acquired encompassing the annular enhancement area and the center nonenhancement area after contrast administration with the following parameters: point-resolved spectroscopy sequence, axial acquisition plane, TE = 35 and 144 ms, TR = 541 ms, number of acquisitions = 64, spectral resolution = 4096 points, voxel size = 8 cm³ (2 × 2 × 2 cm).

We evaluated the following findings on head CT scans: density, the presence of calcifications, hydrocephalus, hemorrhage, perilesional edema, topography, number and size of lesions, and the contrast-enhancement pattern. We evaluated the following on MR imaging: T1 and T2 signals and diffusion, perfusion, and spectroscopy findings.

Similar to Toh et al,²⁷ who studied the “dual rim sign” on SWI in pyogenic abscesses, we also evaluated patients with SWI sequences for the presence of the dual rim sign, which is defined as 2 concentric rims around the central cavities at the margins of lesions, with the outer rim being hypointense, and the inner rim, hyperintense relative to the cavity contents. All imaging findings were assessed by 1 neuroradiologist with 8 years of experience. In addition, the clinical symptoms were accessed through systematic chart review.

FIG 4. Demonstration that the lesions may not present with diffusion restriction (A) or diffusion restriction (B) with a low signal on the ADC map (C).

FIG 5. T1-weighted images after contrast administration demonstrating a small nodule in the cortical-subcortical transition (A), nodular lesion with annular enhancement (B), and multiple nodular lesions with annular enhancement and "daughter cysts" in a complex heterogeneous mass (C).

FIG 6. T2-weighted perfusion shows a lesion with low perfusion (A). T1-weighted perfusion shows the blood-brain barrier breakdown (B).

Furthermore, the study was approved by the Ethics Committee for Clinical Research of the University Hospital Cassiano Antônio de Moraes, Federal University of Espírito Santo, Espírito Santo, Brazil.

RESULTS

We describe 24 patients with a diagnosis of CNS PCM. All patients were men, ranging from 19 to 66 years of age. Approximately half of the patients were between 40 and 59 years of age. Headache was the most common neurologic symptom and was present in 33.3% of the cases. The epidemiology and clinical characteristics are summarized in Table 1.

Twenty-one patients had the pseudotumoral form, defined by the presence of parenchymal lesions with annular or nodular enhancement, while the meningeal pattern was observed in 1 case, and the combined form, in 2 cases. None of the patients had calcifications at the time of the initial neuroimaging. Perilesional edema was present in 90.4% of cases, whereas hydrocephalus and hemorrhage were found in 25% and 13% of cases, respectively. The number of lesions observed in each patient ranged from 1 to 11, with a mean of 3. Eleven patients had between 2 and 5 lesions (Table 2). Most were localized in the frontal lobe (37.5%), followed by the cerebellum (33.3%), parietal lobe (29.1%), occipital lobe (25%), and thalamus (20.8%) (Table 3). Furthermore, 65.2% of the lesions had an axial diameter of >2 cm, and the larger axial diameter of the major lesion ranged from 0.3 to 5.6 cm (Table 2).

Seventeen patients had CT scans showing a total of 53 lesions, of which 56.6% were hypoattenuating, 20.7% were hyperattenuating, and 22.6% had a hypoattenuating center with a hyperattenuating margin (Table 2 and Fig 1). On the other hand, 19 patients underwent MR imaging, in which a total of 61 lesions were observed. The T1-weighted sequence demonstrated that 50.8% were hypointense, 34.4% were hyperintense, and 14.7% were heterogeneous with a hypointense center with a hyperintense margin (Fig 2). On the T2-weighted sequence, 59% were hypointense, 9.8% were hyperintense, and 31.1% had heterogeneous lesions (hyperintense + hypointense)

(Fig 3). Restricted diffusion was present in 47.3% (Fig 4), and the target sign was observed in 1 patient (5.2%). Ring contrast enhancement was observed in 70.8%; nodular enhancement, in 12.5%; both ring and nodular enhancement, in 12.5%; and

leptomeningeal enhancement, in 4.1% of the cases (Table 3 and Fig 5). Moreover, 3 patients underwent MR perfusion imaging, and 2 underwent proton spectroscopy. The perfusion demonstrated decreased relative CBV on DSC and slow and progressive ascending perfusion on dynamic contrast-enhanced imaging in all 3 patients (Fig 6). The spectroscopy demonstrated an increase of lipids and choline in both patients (Table 4 and Fig 7). Of the 5 patients in whom the SWI sequence was performed, 4 showed

the dual rim sign on SWI (Fig 8). The patient who did not show the dual rim sign on SWI had a lesion <2 cm.

Thoracic imaging revealed that all patients presented with thoracic lesions in the form of pulmonary nodules, ground-glass opacities, consolidations, reversed halo sign, bronchiectasis, or lymph node enlargement.

DISCUSSION

To the best of our knowledge, this study presents the largest imaging case series of CNS PCM until now (Fig 9). We describe the neuroimaging findings from 24 patients who were treated in a reference hospital in the State of Espírito Santo.

Peçanha et al²⁸ analyzed 546 patients in a reference hospital from 1978 to 2012 presenting with PCM. The historical case series revealed the involvement of the CNS in 4.5% (22 patients) with the chronic form and 3.3% (2 patients) with the acute/subacute form.

The main patterns of CNS PCM described are the pseudotumoral (90%) and meningeal (10%) forms.^{19-21,29} Moreover, meningitis associated with the pseudotumoral form may occur in 17% of cases, or more rarely, it can be an isolated finding.¹⁹ In our study, we also observed the predominance of the pseudotumoral form (87.5%), while the meningeal form was observed in 4.1%, and the combined form, in 8.3% of the cases.

The meningeal form is characterized by inflammation of the leptomeninges or pachymeninges, generally in the base of the skull, similar to what is observed in tuberculosis meningitis.^{18,29-33} It may be diffuse or localized, isolated, or with dissemination to the parenchyma or nervous roots.

On the other hand, the pseudotumoral form consists of intraparenchymal granulomas, involving both the supratentorial and infratentorial compartments, which may mimic primary tumors, metastases, pyogenic abscesses, or viral and fungal etiologies.^{20,34} The granulomas are frequently irregular (76%), ranging from 10

Table 4: MR imaging findings

Characteristic	Value
MR imaging scans (No. of patients) (%) ^a	
T1-weighted ^b	
Hyperintense lesions	21 (34.4)
Hypointense lesions	31 (50.8)
Hypointense center and hyperintense margin	
T2-weighted ^b	
Hyperintense lesions	6 (9.8)
Hypointense lesions	36 (59.0)
Heterogeneous lesions (hyperintense + hypointense)	19 (31.1)
T1, perfusion ^c	
Slow and progressive ascending	3 (100)
T2, perfusion ^c	
Decreased rCBV	3 (100)
Spectroscopy ^c	
Decrease of NAA	2 (100)
Increase of choline	2 (100)
Increase of lipids	2 (100)
Diffusion-weighted (No. of patients) (%) ^d	
Restricted diffusion	9 (47.3)
Target sign	1 (5.2)

Note:—rCBV indicates relative CBV.

^aFive patients did not have MR imaging scans and were eliminated from the calculations.

^bThe patient with the meningeal form was eliminated from the calculations.

^cOnly 3 patients underwent perfusion, and only 2 underwent spectroscopy.

^dFive patients did not have diffusion and were eliminated from the calculations.

FIG 7. Proton spectroscopy with a TE = 144 ms showing increased lipid and choline peaks, with decreased NAA peaks.

to 45 mm, with mass effect, peripheral enhancement by contrast, and perilesional edema in 82% of the cases.^{20,29,32} In our study, 65.2% of the patients had a granuloma larger than 2.0 cm; the mean diameter of the larger lesion was 2.3 cm with the range 0.3–5.6 cm, showing the same irregularity described in other studies. Similar to the studies described in the medical literature, perilesional edema was present in 90.4% of our patients.

The lesion can be situated in the cerebral hemispheres (67%), cerebellum (25%), brain stem (25%), and spinal cord (4%).^{19,20} In our study, 62.5% of patients had lesions in the cerebral hemispheres; 33.3%, in the cerebellum; and 8.3%, in the brain stem; and no patient had a spinal cord lesion. Gasparetto et al²⁰ demonstrated that 47% of patients had a singular granuloma, 23% had 2 lesions, and 30% had ≥ 3 lesions. In our study, we observed a frequency similar to that of Gasparetto et al; 40.9% of the patients had a single granuloma. The mean number of lesions was 3, and the range was 1–11.

The location of the lesions determines the signals and symptoms in the patients.^{29,35} The 5 most frequent symptoms were epilepsy, hemiparesis, cerebellar signs, headache, and

hydrocephalus.^{19,32} In our patients, the most common symptom was headache, followed by epilepsy.

The pseudotumoral form can assume a compact granulomatous pattern, which is completely solid, or it can have a necrotic center that explains the findings in the MR images. In addition, granulomas do not infiltrate or spread to the adjacent tissue.²⁰ Therefore, necrotic lesions in PCM may resemble pyogenic abscesses, and proton MR imaging with spectroscopy being a noninvasive technique can help distinguish the lesions.^{36,37} Similar to Reis et al,³³ we found a high peak of the lipids and choline in all cases.

MR images show the pseudotumoral lesions consist of variable, hypo- or hyperintense lesions in T1 and T2 sequences. In particular, Reis et al³³ described the presence of a peripheral hyperintense halo in the T1 sequences without contrast in all 8 patients who were included in their research. In our study, this finding was in only 14.7%, demonstrating that it is not as frequent as reported in the above study.

Due to the variability of the composition of a granuloma, the diffusion-weighted sequence may exhibit lesions with or without restriction of water molecules. In our cases, 47.3% of patients had restriction on the diffusion imaging, showing variability as is described.

Similar to Toh et al,²⁷ who found the dual rim sign on SWI in 9 of 12 patients with pyogenic abscesses, we found this sign in all our 4 patients who presented with lesions >2 cm and underwent the SWI sequence, showing that this sign is not specific for pyogenic abscess. The contrast-enhancing rim of bacterial brain abscesses on MR imaging corresponds to the abscess capsule, and the magnetic susceptibility results from the free radicals produced by macrophages. There are a necrotic center and a zone of granulation tissue between the fibrocollagenous capsule and the center of the abscesses. With image coregistration,

FIG 8. SWI sequence showing the dual rim sign. Note the external hypointense halo with an internal hyperintense halo.

FIG 9. Laboratory diagnosis of paracoccidioidomycosis. Fresh examination in Parker-KOH stain shows yeast cells with multiple buds (A). Cultivation of *Paracoccidioides* spp. Left, yeast colonies to 37°C; and right, filamentous colonies to 25°C (B).

Toh et al²⁷ speculated that the hyperintense rims probably represent granulation tissue in pyogenic abscesses. We think this finding, the dual rim, occurs because PCM is also an infection. We suspect that this signal may occur in other infections, not only in bacterial abscesses as initially described by Toh et al. Because an antifungal is the treatment form, histopathologic examination of the margins may not be available in most cases. Thus, this finding is limited by a lack of direct histopathologic correlation with SWI findings, making it difficult to precisely define its origin.

CT images of the pseudotumoral form usually show hypointensifying lesions with ring enhancement after contrast administration and surrounding edema. Calcifications or septations within the lesions might occur in up to 20% of cases.²⁰ With time, pseudotumoral CNS PCM gradually becomes more attenuating in noncontrast tomography and progressively becomes smaller.²⁰

PCM shows a typical granulomatous reaction consisting of multinucleated giant cells mixed with extensive interstitial and conglomerate fibrosis, necrosis, and arterial intimal fibrosis. It subsequently may develop a central area of necrosis, and this may explain the heterogeneous image pattern. The central area of necrosis is initially solid and later may liquefy. On CT, the solid granuloma, without necrosis, may present as isoattenuated or slightly hyperattenuated to the brain parenchyma. On MR imaging, it is hypointense on both T1- and T2WI. The heterogeneity of imaging findings show homogeneous enhancement on post-contrast images. Because the granuloma shows necrosis of its central portion, the images show hypoattenuated lesions on CT, hyperintense on T2WI, with ring enhancement on postcontrast images. Liquid necrotic lesions show restricted diffusion, whereas solid necrotic lesions do not have restriction of diffusion.^{15,20,33}

Similar to Reis et al,³³ all our cases presented with thoracic lesions. Gasparetto et al²⁰ also found thoracic alterations in most patients (88%), a finding that may help in the differential diagnosis.

This study has limitations. Few patients were studied with advanced MR imaging methods like DSC, dynamic contrast-enhancement, spectroscopy, and SWI, with only qualitative analyses, but it paves the way for new studies in the area that may contribute to additional findings in this disease.

CONCLUSIONS

CNS involvement has a variable frequency rate in PCM, and an increase in reports has been observed in recent years.^{19,26} The diagnosis of PCM in the CNS is difficult because of the low sensitivity of diagnostic tests, the isolated forms of PCM in the CNS, the absence of previous systemic infection, and nonspecific symptoms that may be confused with other entities. Nevertheless, imaging examinations though nonspecific, when combined with the epidemiology and clinical manifestations, can play an important role in the diagnosis and evaluation of the disease. Therefore, it should be considered as a differential diagnosis for expansive lesions in the brain or meningitis, particularly in endemic areas.

REFERENCES

1. Kwon-Chung KJ, Bennett JE. **Medical mycology.** *Rev Inst Med Trop Sao Paulo* 1992;34:504–04 [CrossRef](#)
2. Marques-da-Silva SH, Rodrigues AM, de Hoog GS, et al. **Occurrence of *Paracoccidioides lutzii* in the Amazon region: description of two cases.** *Am J Trop Med Hyg* 2012;87:710–14 [CrossRef Medline](#)
3. Turissini DA, Gomez OM, Teixeira MM, et al. **Species boundaries in the human pathogen *Paracoccidioides*.** *Fungal Genet Biol* 2017;106:9–25 [CrossRef Medline](#)
4. Bagagli E, Theodoro RC, Bosco SM, et al. ***Paracoccidioides brasiliensis*: phylogenetic and ecological aspects.** *Mycopathologia* 2008;165:197–207 [CrossRef Medline](#)
5. Terçarioli GR, Bagagli E, Reis GM. **Ecological study of *Paracoccidioides brasiliensis* in soil: growth ability, conidia production and molecular detection.** *BMC Microbiol* 2007;7:92 [CrossRef Medline](#)
6. Wanke B, Aide MA. **Chapter 6: paracoccidioidomycosis.** *J Bras Pneumol* 2009;35:1245–49 [CrossRef Medline](#)
7. Coutinho ZF, Silva D, Lazera M, et al. ***Paracoccidioidomycosis* mortality in Brazil (1980-1995).** *Cad Saúde Pública* 2002;18:1441–54 [CrossRef Medline](#)
8. Ajello L, Polonelli L. **Imported paracoccidioidomycosis: a public health problem in non-endemic areas.** *Eur J Epidemiol* 1985;1:160–65 [CrossRef Medline](#)
9. Kamei K, Sano A, Kikuchi K, et al. **The trend of imported mycoses in Japan.** *J Infect Chemother* 2003;9:16–20 [CrossRef Medline](#)
10. Buitrago MJ, Cuenca-Estrella M. **Current epidemiology and laboratory diagnosis of endemic mycoses in Spain [in Spanish].** *Enferm Infecc Microbiol Clin* 2012;30:407–13 [CrossRef Medline](#)
11. Laccourreye O, Mirghani H, Brasnu D, et al. **Imported acute and isolated glottic paracoccidioidomycosis.** *Ann Otol Rhinol Laryngol* 2010;119:89–92 [CrossRef Medline](#)
12. Onda H, Komine M, Murata S, et al. **Letter: imported paracoccidioidomycosis in Japan.** *Dermatol Online J* 2011;17:11 [Medline](#)
13. Van Damme PA, Bierenbroodspot F, Telgt DS, et al. **A case of imported paracoccidioidomycosis: an awkward infection in the Netherlands.** *Med Mycol* 2006;44:13–18 [CrossRef Medline](#)
14. Walker SL, Pembroke AC, Lucas SB, et al. ***Paracoccidioidomycosis* presenting in the U.K.** *Br J Dermatol* 2007;158:624–26 [CrossRef Medline](#)
15. Rosa Junior M, Baldon IV, Amorim AFC, et al. **Imaging paracoccidioidomycosis: a pictorial review from head to toe.** *Eur J Radiol* 2018;103:147–62 [CrossRef Medline](#)
16. Martinez R. **Epidemiology of paracoccidioidomycosis.** *Rev Inst Med Trop Sao Paulo* 2015;57:11–20 [CrossRef Medline](#)
17. Benard G. **An overview of the immunopathology of human paracoccidioidomycosis.** *Mycopathologia* 2008;165:209–21 [CrossRef Medline](#)
18. Finamor LP, Muccioli C, Martins MC, et al. **Ocular and central nervous system paracoccidioidomycosis in a pregnant woman with acquired immunodeficiency syndrome.** *Am J Ophthalmol* 2002;134:456–59 [CrossRef Medline](#)
19. de Almeida SM, Queiroz-Telles F, Teive HA, et al. **Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings.** *J Infect* 2004;48:193–98 [CrossRef Medline](#)
20. Gasparetto EL, Liu CB, de Carvalho Neto A, et al. **Central nervous system paracoccidioidomycosis: imaging findings in 17 cases.** *J Comput Assist Tomogr* 2003;27:12–17 [CrossRef Medline](#)
21. Magalhaes AC, Bacheschi LA, Caramelli P, et al. ***Paracoccidioidomycosis* of the central nervous system: study of 5 cases by magnetic resonance [in Portuguese].** *Rev Hosp Clin Fac Med Sao Paulo* 1993;48:94–97 [Medline](#)
22. Duarte AL, Baruffa G, Terra HB, et al. **Systemic paracoccidioidomycosis with central nervous system involvement [in Portuguese].** *Rev Soc Bras Med Trop* 1999;32:439–42 [CrossRef Medline](#)
23. Correa RB, Puccioni-Sohler M, Artemenko SR, et al. **An uncommon neurologic presentation in the course of paracoccidioidomycosis: report of a case [in Portuguese].** *Arq Neuropsiquiatr* 1991;49:456–59 [CrossRef Medline](#)

24. de Moura LP, Raffin CN, del Negro GM, et al. **Paracoccidioidomycosis evidencing spinal cord involvement treated with success by fluconazole [in Portuguese].** *Arq Neuropsiquiatr* 1994;52:82–86 [CrossRef Medline](#)
25. Pereira WC, Tenuto RA, Raphael A, et al. **Brain localization of South American blastomycosis: considerations apropos of 9 cases [in Portuguese].** *Arq Neuropsiquiatr* 1965;23:113–26 [CrossRef Medline](#)
26. de Almeida SM. **Central nervous system paracoccidioidomycosis: an overview.** *Braz J Infect Dis* 2005;9:126–33 [CrossRef Medline](#)
27. Toh CH, Wei KC, Chang CN, et al. **Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging.** *AJNR Am J Neuroradiol* 2012;33:1534–38 [CrossRef Medline](#)
28. Peçanha PM, Batista Ferreira ME, Massaroni PM, et al. **Paracoccidioidomycosis: epidemiological and clinical aspects in 546 cases studied in the state of Espírito Santo, Brazil.** *Am J Trop Med Hyg* 2017;97:836–44 [CrossRef Medline](#)
29. Elias J Jr, dos Santos AC, Carlotti CG Jr, et al. **Central nervous system paracoccidioidomycosis: diagnosis and treatment.** *Surg Neurol* 2005;63(Suppl 1):S13–21; discussion S21 [CrossRef Medline](#)
30. Pedro RDJ, Branchini ML, de Lucca RS, et al. **Paracoccidioidomycosis of the central nervous system: apropos of 2 cases [in Portuguese].** *Rev Inst Med Trop Sao Paulo* 1980;22:269–74 [Medline](#)
31. Lorenzoni PJ, Chang MR, Paniago AM, et al. **Paracoccidioidomycosis meningitis: case report [in Portuguese].** *Arq Neuropsiquiatr* 2002;60:1015–18 [CrossRef Medline](#)
32. Francesconi F, Francesconi do Valle AC, Silva MT, et al. **International issues: meningoencephalitis due to Paracoccidioides brasiliensis.** *Neurology* 2008;71:e65–67 [CrossRef Medline](#)
33. Reis F, Collier PP, Souza TF, et al. **Neuroparacoccidioidomycosis (NPCM): magnetic resonance imaging (MRI) findings.** *Mycopathologia* 2013;175:181–86 [CrossRef Medline](#)
34. Rodacki MA, De Toni G, Borba LA, et al. **Paracoccidioidomycosis of the central nervous system: CT findings.** *Neuroradiology* 1995;37:636–41 [CrossRef Medline](#)
35. Teive HA, Zanatta A, Germiniani FM, et al. **Holmes' tremor and neuroparacoccidioidomycosis: a case report.** *Mov Disord* 2002;17:1392–94 [CrossRef Medline](#)
36. Faria AV, Dabus GC, Zanardi VA, et al. **Proton magnetic resonance spectroscopy and magnetic resonance imaging findings in a patient with central nervous system paracoccidioidomycosis.** *J Neuroimaging* 2004;14:377–79 [CrossRef Medline](#)
37. Magalhaes AC, Caramelli P, Silva ED, et al. **Magnetic resonance imaging in intracranial paracoccidioidomycosis.** *J Neuroimaging* 1993;3:216–19 [CrossRef Medline](#)